Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in lilongwe, Malawi

Clinical Infectious Diseases

Volumn 55, Issue 3, 2012, Pages 441-448

  Luebbert, Julia ^a,b   Tweya, Hannock ^c,e   Phiri, Sam ^c   Chaweza, Thom ^c   Mwafilaso, Johnbosco ^c   Hosseinipour, Mina C ^d   Ramroth, Heribert ^a   Schnitzler, Paul ^b   Neuhann, Florian ^a  

^a Institute of Public Health   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c LIGHTHOUSE TRUST   (Malawi)

^d UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^e INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; DRUG TREATMENT FAILURE; DRUG TREATMENT INTERRUTION; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE C; MAJOR CLINICAL STUDY; MALAWI; MALE; NONHUMAN; PRIORITY JOURNAL; RETREATMENT; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VIROLOGICAL FAILURE; VIRUS GENE; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALAWI; MALE; PREVALENCE; TREATMENT FAILURE;

EID: 84863897669     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis438     Document Type: Article

References (36)

1. Harries AD, Zachariah R, Jahn A, Schouten EJ, Kamoto K. Scaling up antiretroviral therapy in Malawi-implications for managing other chronic diseases in resource-limited countries. J Acquir Immune Defic Syndr 2009; 52(Suppl 1):S14-6.
2. Ministry of Health Malawi. ART report 2009 Q4. Available at: http://www.hivunitmohmw.org/Main/AntiretroviralTherapy. Accessed 2 November 2011.
3. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis 2011; 11:942-51.
4. Glass TR, De GS, Weber R, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006; 41: 385-92.
5. Antinori A, Cozzi-Lepri A, Ammassari A, et al. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther 2004; 9:291-6.
6. Carrieri MP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther 2003; 8:585-94.
7. Garcia de OP, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30:105-10.
8. Keiser O, Anastos K, Schechter M, et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13:870-9.
9. Kiguba R, Byakika-Tusiime J, Karamagi C, Ssali F, Mugyenyi P, Katabira E. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. J Acquir Immune Defic Syndr 2007; 45:218-23.
10. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146:564-73.
11. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapineor efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38:1311-6.
12. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 2007; 45:1492-8.
13. USAID Aidstar-One project. Patel A, Hirschhorn L, Fullem A, Ojikutu B, Oser R. Adult adherence to treatment and retention in care. Available at: http://www.aidstar-one.com/sites/default/files/AdultAdherenceTB-Final.pdf. Accessed: 4 April 2012.
14. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15(Suppl 1):1-15.
15. Hedt BL, Wadonda-Kabondo N, Makombe S, et al. Early warning indicators for HIV drug resistance in Malawi. Antivir Ther 2008; 13 (Suppl 2):69-75.
16. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.
17. Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44:128-34.
18. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-10.
19. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-52.
20. Kamoto K, Aberle-Grasse J. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008; 13(Suppl 2):83-7.
21. Maphalala G, Okello V, Mndzebele S, et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther 2008; 13(Suppl 2):95-100.
22. Ministry of Health Malawi. Malawi integrated guidelines for providing HIV services. Available at: http://www.hivunitmohmw.org/Main/AntiretroviralTherapy. Accessed 25 March 2012.
23. Ministry of Health Malawi. Treatment of AIDS-guidelines for the use of antiretroviral therapy in Malawi. 3rd ed. Available at: http://www.hivunitmohmw. org/Main/AntiretroviralTherapy. Accessed 2 November 2011.
24. WHO. WHO recommendations for clinical mentoring to support scale-up of HIV care, antiretroviral therapy and prevention in resource-constrained settings. Available at: http://www.who.int/hiv/pub/meetingreports/ clinicalmentoring/en/index.html. Accessed 2 November 2011.
25. Tweya H, Gareta D, Chagwera F, et al. Early active follow-up of patients on antiretroviral therapy (ART) who are lost to follow-up: the "Back-to-Care" project in Lilongwe, Malawi. Trop Med Int Health 2010; 15(Suppl 1):82-9.
26. Kantor R, Katzenstein D. Drug resistance in non-subtype B HIV-1. J Clin Virol 2004; 29:152-9.
27. Weigel R, Estill J, Egger M, et al. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS 2012; 26:365-73.
28. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15(Suppl 1):1-15.
29. Wadonda-Kabondo N, Myo K, Devos J, et al. Prevalence of HIV-1 drug resistance before treatment initiation and at 12 months after treatment initiation in four antiretroviral treatment sites in the Malawi ART program. Clin Infect Dis 2011.
30. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-9.
31. Dagnra AY, Vidal N, Mensah A, et al. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. J Int AIDS Soc 2011; 14:30.
32. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: highlevel nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-34.
33. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 2010; 24: 1679-87.
34. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004; 36:1100-2.
35. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixeddose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-71.
36. Veenstra N, Whiteside A, Gibbs A, et al. HEARD: unplanned ART interruptions in southern Africa: what can we do to minimise the long-term risks? Final Report 2010. Available at: http://www.heard. org.za/downloads/ unplanned-art-interruptions-policy-brief.pdf. Accessed 25 March 2012.